Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.


Player Avatar shortyal (< 20) Submitted: 1/19/2013 7:15:14 PM : Outperform Start Price: $29.90 DVAX Score: -27.37

this has several studies in the pipeline, they have to re visit the FDA panel, but they rated 8-5, they will get the approval and this stock will get the big cap investors back.

Featured Broker Partners